Moody's assigns B3 CFR to Depomed; stable outlook
Rating Action: Moody's assigns B3 CFR to Depomed; stable outlook. Global Credit Research- 13 Jul 2017. New York, July 13, 2017-- Moody's Investors Service assigned a B3 Corporate Family Rating and B3-PD Probability of Default Rating to Depomed, Inc. Moody's also assigned an SGL-2 Speculative Grade Liquidity Rating and Ba3 ratings to the company's proposed $385 million senior secured credit facilities.Depomed is a pharmaceutical company focused on pain and other central nervous system conditions. The company's business includes the following products marketed in the U.S. for various pain states: Gralise
Moody's Investors Service is a leading provider of credit ratings, research, and risk analysis. Moody's commitment and expertise contributes to transparent and integrated financial markets, protecting the integrity of credit. Our ratings and analysis track debt covering more than:
- 130 countries
11,000 corporate issuers
21,000 public finance issuers
76,000 structured finance obligations
Credit ratings and research help investors analyze the credit risks associated with fixed-income securities. Such independent credit ratings and research also contribute to efficiencies in fixed-income markets and other obligations, such as insurance policies and derivative transactions, by providing credible and independent assessments of credit risk.
Moody’s default studies validate our predictive ratings. Our published research and investor briefings draw thousands of attendees each year and keep investors current with the rationale underlying our credit opinions.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.